DEM BioPharma Appoints Miriam Merad, M.D., Ph.D.,
to Scientific Advisory Board
CAMBRIDGE, Mass., March 14, 2022-- DEM BioPharma, Inc. (DEM Bio), an immune-oncology company
developing therapies that target signals on cancer cells and macrophages to eliminate cancer, today
announced the addition of Miriam Merad, M.D., Ph.D., to its Scientific Advisory Board.
“Dr. Merad is an internationally renowned physician-scientist and a leader in myeloid biology focused onidentifying innate immune cells that can be harnessed to treat cancer and other human diseases,” said
Nenad Grmusa, CEO of DEM Bio. “We are excited to welcome her to DEM Bio and look forward tobenefiting from her expertise and guidance as we further the development of our platform and advancenovel targets towards oncology therapeutic development.”“DEM Bio’s platform is built on a cutting-edge scientific foundation, and the company’s unique approachof discovering and targeting novel ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells andmacrophages has the potential to reveal unexplored immune pathways for treating cancer,” said Dr.
Merad. “I am delighted to join this team of innovators and help advance DEM Bio’s immuno-oncology
drug target portfolio.”
Dr. Merad is the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in
New York and the Director of the Mount Sinai Human Immune Monitoring Center (HIMC), which she
founded. Her research over the past 20 years has focused on understanding the mechanisms that
control the development and functional identity of dendritic cells and macrophages during homeostasis,and examining how these regulations are changed in cancer and inflammatory diseases. Dr. Merad iscredited with identifying the tissue resident macrophage lineage and revealing its distinct role in organ
physiology and pathophysiology. She has authored more than 200 primary papers and reviews in highprofile journals. Dr. Merad is the recipient of the William B. Coley Award for Distinguished Research in
Basic and Tumor Immunology. In 2020, she was elected to the National Academy of Sciences inrecognition of her contributions to the field of immunology and in 2023, she was named President ofthe International Union of Immunological Societies (IUIS). Dr. Merad obtained her M.D. at theUniversity of Algiers and completed her residency in hematology/oncology at the University of Paris VII.
She holds a Master’s degree in biotechnology and a Ph.D. in immunology from Stanford University andUniversity Paris VII.
About DEM BioPharma Inc.

DEM Bio is pioneering the next generation of immunotherapeutics that unleash the innate immune
system to eliminate tumors by targeting ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells,
macrophages and other myeloid effector cells. The company’s approach builds on the groundbreaking
functional genomics research and discoveries in macrophage biology from its scientific co-founders: Drs.
Jonathan Weissman and Kipp Weiskopf of the Whitehead Institute and Dr. Michael Bassik of Stanford
University. The proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) utilizes
CRISPR-based functional genomic screens in human cancer cells and/or primary macrophages todiscover and validate new DEM and EM signals that could profoundly induce and enhance cancer cell
elimination through increased phagocytosis. For further information, see: https://dembiopharma.com/.
ContactsHolly Hancock
MacDougall Advisors
hhancock@macdougall.bio(781) 235-3060